Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
29
Views
2
CrossRef citations to date
0
Altmetric
Review

Emergence of targeted immune therapies for systemic lupus

Joan T Merrill Oklahoma Medical Research Foundation, Clinical Pharmacology Research Program, 825 Northeast 13 St., Oklahoma City, OK 73104, USA. [email protected]
Pages 53-65 | Published online: 22 Apr 2005

Bibliography

  • BARR SG, ZONANA-NACACH A, MAGDER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. (1999) 42(12):2682–2688.
  • ••A systematic study of diverse clinicalpatterns in SLE.
  • Trends in Deaths from Systemic Lupus Erythematosus - United States, 1979-1998 morbidity and mortality weekly report. (2002) 51(17): 371–374.
  • STOJANOVICH L, STOJANOVICH R, KOSTICH V, DZJOLICH E: Neuropsychiatric lupus favourable response to low dose Iv. cyclophosphamide and prednisolone (pilot study). Lupus. (2003) 12:10–15.
  • ZONANA-NACACH A, BARR SG, MAGDER LS, PETRI M: Damage in systemic lupus and its association with corticosteroids. Arthritis Rheum. (2000) 43:1801–1808.
  • FISHER DE, BICKEL WH: Corticosteroid-induced a vascular necrosis. A clinical study of seventy-seven patients. Bone Joint Surg. Am. (1971) 53:859–873.
  • BADSHA H, EDWARDS CJ: Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin. Arthritis Rheum. (2003) 32:370–377.
  • TAM LS, GLADMAN DD, HALLETT DC, RAHMAN P, UROWITZ MB: Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. Rheumatol (2000) 27:2142–2145.
  • BORBA EF, BONFA E: Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol (2001) 28:780–785.
  • LAKSHMINARAYANAN S, WALSH S, MOHANRAJ M, ROTHFIELD N: Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. RheumatoL (2001) 28:102–108.
  • LEVY RA., VILELA VS, CATALDO MJ et al.: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus (2001) 10:401–404.
  • BARDANA EJ JR, PORTER GA, PIROFSKY B, GOURLEY RT, BAYRAKCI C: Azathioprine in steroid-insensitive nephropathy. Am. J. Med. (1970) 49: 789–800.
  • DRINKARD JP, STANLEY TM, DORNFELD L et al.: Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy. Medicine (Baltimore) (1970) 49:411–432.
  • EL HACHMI M, JADOUL M, LEFEBVRE C, DEPRESSEUX G, HOUSSIAU FA: Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus (2003) 12:692–696.
  • CHAN TM, LI FK, HAO WK et el.: Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus (1999) 8:545–551.
  • CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N Engl J. Med. (2004) 350: 971–980.
  • MOK CC, HO CT, CHAN KW, LAU CS, WONG RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46:1003–1013.
  • ABU-SHAKRA M, SHOENFELD Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus (2001) 10:152–153.
  • SATO El: Methotrexate therapy in systemiclupus erythematosus. Lupus (2001) 10:162–164.
  • REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10:480–483.
  • HU W, LIU Z, SHEN S et al.: Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. (2003) 116:1827–1830.
  • DAMMACCO F, DELLA CASA A et al.: Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int. J. Clin. Lab. Res. (2000) 30:67–73.
  • STEINBERG AD, KALTREIDE RHB, STAPLES PJ, GOETZL EJ, TALAL N, DECKER JL: Cyclophosphamide in lupus nephritis: a controlled trial. Ann. Intern. Med. (1971) 75:165–171.
  • HOUSSIAU FA, VASCONCELOS C, D'CRUZ D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121–2131.
  • BROOK CG, EVANS PR: Psychosis in systemic lupus erythematosus (SLE) and the response to cyclophosphamide. Proc. R. Soc. Med. (1969) 62:912.
  • FLANC RS, ROBERTS MA, STRIPPOLI GF, CHADBAN SJ, KERR PG, ATKINS RC: Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. (2004) 43:197–208.
  • MILLER JJ 3RD, -WILLIAMS GF, LEISSRING JC: Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am. J. Med. (1971) 50:530–535.
  • WECHSLER B, HUONG DU LT, PIETTE JC: Is there a role for antithrombotic therapy in the prevention of pregnancy loss? Haemostasis (1999) 29:S1:112–20.
  • MERRILL JT: Regulation of the vasculature: clues from lupus. Curr .0pin. RheumatoL 2002) 14:504–509.
  • FABBRI P, CARDINALI C, GIOMI B, CAPRONI M: Cutaneous lupus erythematosus: diagnosis and management. Am. J. Clin. DermatoL (2003) 4:449–465.
  • TRAYNOR AE, SCHROEDER J, ROSA RM, et al.: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a Phase I study. Lancet (2000) 356:701–707.
  • HASHIMOTO N, IWASAKI T, SEKIGUCHI M et al.: Autologous hematopoietic stem cell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis. H. Bone Marrow Transplant (2004) 33:863–866.
  • KANG I, PARK SH: Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. RheumatoL (2003) 15:528–534.
  • BARR RG, SELIGER S, APPEL GB et al.: Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ ethnicity. NephroL Dial. Transplant (2003) 18:2039–2046.
  • CORTES-HERNANDEZ J, ORDI-ROS J,LABRADOR M et al.: Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus (2003) 12:287–296.
  • ISENBERG D, LECKIE MJ: Biological treatments for systemic lupus erythematosus. Scand. j RheumatoL (2002) 31:187–191.
  • BOGDANOVIC R, NIKOLIC V, PASIC S et al.: Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr. NephroL (2004) 19:36–44.
  • ROSENWALD M: No favorite in race totreat lupus the Washington Post (2004) Monday, September 6:E01.
  • ARBUCKLE MR, REICHLIN M, HARLEY JB, JAMES JA: Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand. j ImmunoL (1999) 50:447–455.
  • JAMES JA, HARLEY JB: A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J. ImmunoL (1998) 160:502–508.
  • KIM SJ, GERSHOV D, MAX, BROT N, ELKON KB: Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann. NY Acad. Sci. (2003) 987:68–78.
  • RAVIRAJAN CT, PITTONI V, ISENBERG DA: Apoptosis in human autoimmune diseases. Int. Rev. ImmunoL (1999) 18:563-589. Review of the role of apoptosis in autoimmunity with fundamental implications for SLE.
  • GRODZICKY T, ELKON KB: Apoptosis:a case where too much or too little can lead to autoimmunity. Mt. Sinai. J. Med. (2002) 69:208–219.
  • BAUMLER C, KIM GO, ELKON KB: Growth regulation of activated lymphocytes: defects in homeostasis lead to autoimmunity and/or lymphoma. Rev. Immunogenet. (2000) 2:283–290.
  • KAY MM, GOODMAN J: Immunoregulation of cellular lifespan: physiologic autoantibodies and their peptide antigens. Cell MoL Biol. (2003) 49:217–243.
  • GARDNER-THORPE J, ITO H, ASHLEY SW, WHANG EE: Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas (2003) 27:180–189.
  • STAFFORD HA, ANDERSON CJ, REICHLIN M: Unmasking of anti-ribosomal P autoantibodies in healthy individuals./ ImmunoL (1995) 155:2754-2761. Evidence that autoantibodies are found in healthy people, changing the paradigm for SLE pathogenesis from an aberrant immune response to a disregulated one.
  • BOUVET JP, STAHL D, ROSE S, QUAN CP, KAZATCHKINE MD, KAVERI SV: Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. (2001) 16:163–172.
  • MERRILL JT: Dehydroepiandrosterone, asex steroid metabolite in development for systemic lupus erythematosus. Expert Opin. Investig. Drugs (2003) 12:1017–1025.
  • PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2002) 46:1820–1829.
  • CHANG DM, LAN JL, LIN HY LUO SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2924-2927. 63
  • DING L, ZHAO M, ZOU W, LIU Y, WANG H: Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus (2004) 13:113–118.
  • LI L, WANG H, UN S: Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Zei Zhi (2002) 41:476-479 (abstract only: paper not available).
  • CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N EngL Med. (2004) 350:971–980.
  • •Evidence for alternative treatments to cydophosphamide in lupus nephritis.
  • HARZALLAH K, BADID C, FOUQUE D, LEFRANCOIS N, TOURAINE JL, LAVILLE M: Efficacy of mycophenolate mofetil on recurrent glomerulonephritis after renal transplantation. Clin. NephroL (2003) 59:212–216.
  • ZHAO M, CHEN X, CHEN Y et el.: Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (2003) 8:2–10.
  • CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N EngL J. Med. (2000) 343:1156–1163.
  • MERRILL JT: UP 1082: a toleragen for Hughes syndrome. Lupus (2004) 13:335–338.
  • WEISMAN MH, BLUESTEIN HG, BERNER CM, DE HAAN HA: Reduction in circulating dsDNA antibody titer after administration of UP 394.1 RheumatoL (1997) 24:314–318.
  • •Evidence for a biological effect of Riquent.
  • WALLACE DJ, TUMLIN JA: UP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus.Lupus (2004) 13:323–327.
  • ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: UP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48:442–454.
  • SPERTINI F, LEIMGRUBER A, MOREL B et al.: Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. RheumatoL (1999) 26:2602–2608.
  • WAISMAN A, RUIZ PJ, ISRAELI E et al.:Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Nat. Acad. Sci. (1997) 94(9):4620–4625.
  • •Evidence from a murine model supporting the potential use of CR1 peptide in lupus-like disease.
  • DAYAB M, SEGAL R, STHOEGER Z et al: J. Clin. ImmunoL (2000) 20:187–192.
  • GRAMMER AC, SLOTA R, FISCHER R et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. (2003) 112:1506–1520.
  • HARIGAI M, HARA M, FUKASAWA C et al.: Responsiveness of peripheral blood B cells to re-combinant CD40 ligand in patients with systemic lupus erythematosus. Lupus (1999) 8:227–233.
  • UHM WS, NA K, SONG GW et al.: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (2003) 42(8):935–938.
  • KUROIWA T, SCHLIMGEN R, ILLEI GG, BOUMPAS DT: Monocyte response to Thl stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clin. ImmunoL (2003) 106:65–72.
  • KATO K, SANTANA-SAHAGUN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. (1999) 104:947–955.
  • HIGUCHI T, AIBAY, NOMURA T et al.: Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. ImmunoL (2002) 168:9–12.
  • QUEZADA SA, ECKERT M, ADEYI OA, SCHNED AR, NOELLE RJ, BURNS CM: Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis. Rheum. (2003) 48:2541–2554.
  • KAIRAITIS L, WANG Y, ZHENG L, TAY YC, WANG Y, HARRIS DC: Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int. (2003) 64:1265–1272.
  • WANG X, HUANG W, SCHIFFER LE, MIHARA M, AKKERMAN A, HIROMATSU K, DAVIDSON A: Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. (2003) 48:495–506.
  • KALLED SL, CUTLER AH, BURKLY LC: Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J. ImmunoL (2001) 167:1740–1747.
  • BRAMS P, BLACK A, PADLAN EA et al.: A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int. ImmunopharmacoL (2001) 1:277–294.
  • HUANG W, SINHA J, NEWMAN J et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. (2002) 46:1554–1562.
  • DAVIS JC JR, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. j RheumatoL (2001) 28:95–101.
  • KALUNIAN KC, DAVIS JC JR, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:3251–3258.
  • BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Arthritis Rheum. (2003) 48:719-727.
  • STOHL W, METYAS S, TAN SM et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. (2003) 48:3475–3486.
  • STOHL W: SUE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther. (2003) 5:136–138.
  • KAWASAKI A, TSUCHIYA N, FUKAZAWA T, HASHIMOTO H, TOKUNAGA K: Analysis on the association of human BUYS (BAFF, 64 TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. (2002) 3:424–429.
  • ROSCHKE V, SOSNOVTSEVA S, WARD CD et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. Immunol (2002) 169:4314–4321.
  • SESHASAYEE D, VALDEZ P, YAN M, DIXIT VM, TUMAS D, GREWAL IS: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 18:279–288.
  • BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 483:253–265.
  • •Characterisation of LymphoStat-B.
  • LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673–2677.
  • ANOLIK JH, CAMPBELL D, FELGAR RE, et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455–459.
  • WEIDE R, HEYMANNS J, PANDOR FA, KOPPLER H: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 12:779–782.
  • ANOLIK J, SANZ I, LOONEY RJ: B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol Rep. (2003) 5:350–356.
  • LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II does-escalation trial of rituximab. Arthritis Rheum. (2002) 50: 2580–2589.
  • •Phase I/II study of rituximab in SLE.
  • KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. immunobio/ogy (2002) 206:519–527.
  • SHANAFELT TD, MADUEME HL, WOLF RC, TEFFERI A: Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo. Clin. Proc. (2003) 78:1340–1346.
  • ZAJA F, VIANELLI N SPEROTTO A, DE VITA S, et al.: B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica (2003) 88:538–546.
  • CATE R SMIERS FJ, BREDIUS RG, LANKESTER AC, et al.: Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (2004) 43:244.
  • SAITO K, NAWATA M, NAKAYAMADA S, TOKUNAGA M, TSUKADA J, TANAKA Y: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus (2003) 12:798–800.
  • FRA GP, AVANZI GC, BARTOLI E: Remission of refractory lupus nephritis with a protocol including rituximab. Lupus (2003) 12:783–787.
  • GLADMAN DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Wellesley Hospital, Toronto, Ontario, Canada. Curr. Opin. Rheumatol (1994) 6(5):487–492.
  • GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol (1994) 21: 1468–1471.
  • HAY EM, BACON PA, GORDON C et al.: The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. (1993) 86:447–458.
  • ••Description and study of the BILAGinstrument for measuring disease activity in SLE.
  • GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J. Rheumatol (1992) 19:608–611.
  • BENCIVELLI W, VITALI C, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Clin. Exp. Rheumatol (1992) 10:549–554.
  • WARD MM, MARX AS, BARRY NN: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Medical Service, VA Palo Alto Health Care System, CA 94304, USA. J. Rheumatol (2000) 27:664–670.
  • CORZILLIUS M, FORTIN P, STUCKI G: Responsiveness and sensitivity to change of SLE disease activity measures. Lupus (1999) 8:655–659.

Websites

  • http://www.ajmc.com/Article. CLARKE A, The economic impact of SLE Am. J. of Managed Care (2001).
  • http://www.lupus.org/education/stats.html Statistics about Lupus. Lupus Foundation of America, Inc.
  • ••Some data regarding the economic impactof SLE can be derived from these surveys.
  • http://www.bio.com/store/ product.jhtml?id=prod580004. Theta Reports Autoimmune Disease Therapeutics Worldwide: Markets & Developments.
  • http://www.genelabs.com/development/ prestaraLupus.html. Genelabs Technologies website.
  • http://www.aspreva.com/ products_in_development.html. Aspreva website.
  • http://www.roche.com/med-cor- 192003-10-22b. Roche website.
  • http://www.ljpc.com/ product_research_thromb.html.La Jolla Pharmaceuticals website.
  • http://www.tevapharm.com/research/ products_np.asp. Teva website.
  • http://www.hgsi.com/products/index.html. Human Genome Sciences website.
  • http://www.gene.com/gene/pipeline/status-immunology/rituxan/. Genentech website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.